A recent UK documentary highlights the need for a service that protects patients and works with their trusted healthcare providers.

Lower prices negotiated and provided as part of our ongoing mission to make medicines more accessible. 
 

2018 has been a good year for new cancer treatments says the U.S. AACR. 
 

Kisqali is now the only CDK4/6 inhibitor for use with an aromatase inhibitor for the treatment of pre-, peri- or postmenopausal women in the US.

The approval marks a significant advance in the field of neurology — and one that migraine patients will no doubt welcome.

The new preventive medicine for migraine Aimovig (erenumab) has been approved by the EMA. Read more...
 

You might have heard about a new medicine that’s just been approved to treat migraine. Here’s what you need to know.

7 need-to-knows about migraine as well as some updates on the latest treatment developments

Find out about what it means to order and receive temperature-controlled medicines.

The dramatic before-and-after images show eight men's incredible response to cutting-edge treatment. 

A closer look at the function and efficicacy of niraparib as a maintenace treatment.

It’s believed that this immunotherapy and its dual approach to fighting cancer will be a notable complement to existing immuno-oncology treatments.

Researchers believe these differences are due to a reduced immunosuppressive tumor environment in older patients.

The latest approval renders the previous 'temporary approval' a full approval, without further results needed.

The 52% (95% CI, 41-62) ORR included a complete response rate of 40% and a partial response rate of 12%.

The FDA has approved a wearable device to treat withdrawal symptoms such as agitation, anxiety, depression, and opiate cravings.

Researchers say the addition of Keytruda (pembrolizumab) in this study almost doubled the response rate of chemo for patients with NSCLC.

The study showed that the relative survival gain almost doubled in men, compared to female patients, regardless of the type of cancer and drugs given.

Our quarterly review was an opportunity to take stock and support an organisation fuelled by a mission aligned to ours: to make the lives of other human beings better.

"My role is to guide a patient or their loved ones (sometimes that’s a partner, but it could also be a friend, relative or a doctor) through the process of what we do for them."

 

Tagrisso (osimertinib) has been approved in Europe to treat Epidermal Growth Factor Receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as a first-line treatment. 

A new preventive migraine treatment, Aimovig (erenumab-aooe), poses promising possibilities for some migraine sufferers.

New clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.